News
Health Canada approves Kesimpta to treat relapsing remitting multiple sclerosis. Novartis
Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Kesimpta (ofatumumab) for the treatment of adults with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.
Kesimpta is the first and only targeted B-cell therapy that can be self-administered subcutaneously once a month via the Sensoready autoinjector pen.
Condition: Multiple Sclerosis
Type: drug